A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-03

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Researchers are looking for a better way to treat and prevent cardiac surgery-associated acute kidney injury (CSA-AKI) in people who undergo heart surgeries.

CSA-AKI is a common complication in people undergoing heart surgeries, where the kidneys stop working properly. CSA-AKI risk factors include older age and alongside diseases such as kidney disease and diabetes. Longer time with heart-lung machine during heart surgeries also increases the occurrence of CSA-AKI.

In this study, researchers want to better understand how CSA-AKI develops (also known as the mechanisms involved in the development of CSA-AKI) in people under heart surgeries, the presence of certain biomarkers in the body, especially with a focus on the early hours and days after the surgery. (A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.) These biomarkers will be compared in participants who develop CSA-AKI within a week after heart surgery with the participants who do not develop CSA-AKI. The relationship with biomarkers will be determined by examining participants' blood and urine samples before and after surgery.

This may help researchers better understand CSA-AKI, identify potential treatment targets and develop possible treatments to prevent CSA-AKI.

Participants in this study will be people who have heart surgery already scheduled by their own doctors and have a risk of developing CSA-AKI. Participants will not receive any treatment as part of this study. They will undergo the heart surgery and related medical processes as per their normal medical treatment and management.

Each participant will be in the study for up to 2 months. During the study, the doctors and their study team will:

* collect participants' blood and urine samples before and after surgery
* assess participants' medical records and test reports during hospitalization
* monitor overall health of the participants throughout the study

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarkers of Acute Kidney Injury Following Cardiac Surgery

NCT04387149

Novel Biomarkers of Acute Kidney Injury Following Cardiac Surgery

UNKNOWN

Cardiovascular Surgery Early Prediction System for AKI :CARDS-AKI Registry

NCT07330453

Cardiovascular Surgery

NOT_YET_RECRUITING

Machine Learning Predict Acute Kidney Injury in Patients Following Cardiac Surgery

NCT04966598

Machine Learning Acute Kidney Injury

COMPLETED

The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery

NCT02496234

Coronary Artery Disease

COMPLETED

Prediction of Acute Kidney Injury After Cardiac Surgery With Cardiopulmonary Bypass

NCT07343830

Acute Kidney Injury Cardiac Surgery Cardiopulmonary Bypass Surgery +1 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Surgery-associated Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cardiac surgery

Patients scheduled for cardiac surgery with cardiopulmonary bypass will be managed according to local standard medical care. Blood and urine will be obtained pre-surgery and post-surgery for analysis.

Group Type EXPERIMENTAL

No investigational study intervention

Intervention Type OTHER

No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood (not exceeding 200 mL) and urine samples and of available clinical data are the only activities performed in addition.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No investigational study intervention

No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood (not exceeding 200 mL) and urine samples and of available clinical data are the only activities performed in addition.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be at least 18 years of age at the time of signing the informed consent form (ICF).
* Participants who are scheduled for hospital admission for any of the following cardiovascular surgery interventions, alone or in combination, involving cardiopulmonary bypass (CPB):

* Aortic, mitral, or tricuspid valve surgery (repair or replacement)
* Aortic surgery
* ≥3 coronary artery bypass grafts
* Participant with: chronic kidney disease (CKD): 30 ≤ estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73 m\^2

Exclusion Criteria

* Emergency surgery situation
* Anemia - hemoglobin \<10 g/dL
* Clinical signs of systemic infection or other infection requiring anti-infective treatment (viral, bacterial, fungal, parasitic; single-dose prophylaxis allowed)
* Systemic immunosuppressive or anti-inflammatory treatment including corticosteroids \>10 mg prednisolone equivalent/day
* Any anti-cancer treatment within 3 months (e.g. immunotherapy, chemotherapy, radiotherapy)
* Major surgery within 2 months
* AKI within the last month
* Prior renal transplants or RRT
* Planned use of contrast media within 5 days prior to surgery or during surgery
* Patient included in an interventional clinical trial involving a pharmacological intervention
* Any reason that would make participation unadvisable, at the discretion of the investigator.
* Autoimmune disorders such as anti-glomerular basement membrane (anti-GBM) diseases, systemic lupus erythematosus, chronic rheumatic heart diseases, acute rheumatic heart pericarditis, endocarditis, myocarditis, rheumatic mitral valve diseases, rheumatic aortic valve diseases

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No